Abarceo Pharma
Abarceo Pharma is a spin-out of Lund University Diabetes Center founded in 2017 by Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi world-renowned scientists in diabetes research and beta-cell biology. Abarceo Pharma has identified a novel diabetes target VDAC1 located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce their insulin again, naturally. The company founders were the first to describe that voltage-dependent anion channel 1 (VDAC1) is dysfunctional and presents a novel target in Type 2 Diabetes (T2D). VDAC1 is a key mitochondrial protein regulating the energy production in cells and has been implicated in multiple diseases with underlying mitochondrial dysfunction including neurodegenerative and cardiovascular disease (CVD). These diseases are closely related to T2D and are often referred to as comorbidities.
Abarceo Pharma is developing a small molecule technology platform for the treatment of mitochondrial dysfunction, with an initial focus on T2D.
Amplio Pharma
- CEO: Marguerite Mensonides
- Chairman of the board: Rob Mayfield
Amplio Pharma is a rare opportunity to invest in a de-risked, patent-protected asset with the potential to redefine first-line rheumatoid arthritis treatment. NovoBioJect builds on methotrexate, the established global standard, and has already generated human biomarker data supporting superior efficacy. Rather than competing in crowded biologics markets, it aims to replace the current first-line therapy, creating access to a multi-billion-dollar market opportunity. With Phase IIa ahead, €10 million of Series A financing, and a defined acquisition pathway by major immunology players, Amplio offers investors a realistic near-term exit opportunity and the potential for outsized returns.
AlzeCure
- CEO: Martin Jönsson
- Chairman of the board: Thomas Pollare
AlzeCure® is a Swedish biotech company developing new, innovative drug therapies for severe diseases and conditions affecting the central nervous system, such as Alzheimer’s disease and pain – indications where available treatment options today are very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several drug candidates in parallel based on three research platforms: NeuroRestore®, Alzstatin® and Painless. AlzeCure has recently signed collaboration and outlicensing agreements with Eli Lilly on the Alzstatin platform, and with QuantumCell ApS on the NeuroRestore platform.
Biovica
- CEO: Theis Kipling
- Chairman of the board: Jeff Borcherding
Biovica develops DiviTum® TKa, a blood-based biomarker test that tells oncologists within weeks, not months, whether a metastatic breast cancer treatment is working. Instead of waiting ~12 weeks for the first imaging scan, a simple blood draw gives an early signal of treatment response, enabling faster course-correction for patients and supporting smarter dosing and patient stratification for pharma partners. Our promise: replace a long, uncertain wait with an early, actionable answer, so fewer patients stay on treatments that aren’t working, and more decisions get made when they still matter most.
Biomedical Bonding
- CEO: Michael Malkoch
- Chairman of the board: Michael Malkoch
Every second, more than five people somewhere in the world break a bone. Most of us will break at least two in a lifetime. Fracture is not a niche indication. It is one of the few medical events almost every human being will experience.Yet the repair has barely changed in seventy years. A rigid metal plate is manufactured long before the injury exists, chosen from a catalogue of sizes and bent by hand to approximate a bone it was never made for. The compromise is sharpest where the need is greatest. In osteoporotic bone, screws lose their purchase, and a plate many times stiffer than the bone it supports shields that bone from load and concentrates stress at its ends, where the next fracture begins.
Biomedical Bonding AB is a Swedish MedTech company founded to remove that compromise. Bonevolent®, a patented light-cured composite platform spun out of KTH Royal Institute of Technology in Stockholm and grounded in more than a decade of research and peer-reviewed biomechanical evidence, allows the surgeon to build a load-bearing fixator directly on the bone and cure it on demand. The implant is shaped to the fracture rather than the fracture to the implant, and it cures to a stiffness close to bone itself.The human skeleton has 206 bones, and almost every one of them can break in a way that a fixator shaped in theatre fits better than anything made in advance. That is the scale BMB is building towards: veterinary market entry in 2027, the first human fracture fixed in 2028, followed by market launch in 2030.
BioInvent International
- CEO: Martin Welschof
- Chairman of the board: Leonard Kruimer
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of solid tumors and hematological cancer. Its validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company’s own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.
Cantargia
- CEO: Hilde H. Steineger
- Chairman of the board: Magnus Persson
Cantargia is a clinical-stage biotech company developing antibody therapies targeting IL1RAP, a key driver in cancer and inflammatory diseases. Our lead asset, nadunolimab, shows promising clinical activity in hard‑to‑treat cancers such as pancreatic cancer, addressing a major unmet medical need. In parallel, CAN10 creates significant value through a global partnership with Otsuka, including milestone payments and royalties. With a differentiated mechanism, advancing clinical programs, and strong partnering potential, Cantargia offers a compelling opportunity in high‑impact therapeutic areas.
Edvince
- CEO: Peter Selin
- Chairman of the board: Erik Kinnman
Edvince is a clinical-stage biotech developing novel treatments in the field of stroke. Edvince’s lead program, EDV2209 is a first-in-class candidate drug that has completed a clinical phase 1b/2a trial in patients with subarachnoid hemorrhage (SAH). EDV2209 has obtained Orphan Drug Designation in SAH by both FDA and EMA. The company is now planning to advance the program into Phase 2b and, in connection with this, list the company on NGM during Q4 2026.
Endoriz
- CEO: Hanne Evenbratt
- Chairman of the board: Sara Malcus
Endoriz is developing a next‑generation therapy for hypothyroidism, a common chronic disease where many patients remain symptomatic despite standard treatment. Millions—predominantly women—continue to suffer from fatigue, cognitive impairment, and reduced quality of life with no effective alternative. Endoriz addresses this unmet need with a patent‑pending, extended‑release therapy designed to restore natural hormone balance in a safe and controlled way. The program is structured to enter clinical development directly at Phase II, significantly reducing development time, cost, and risk. This positions Endoriz for rapid value inflection and high‑value partnering within a large, established endocrine market.
Elicera Therapeutics
- CEO: Johan Liwing
- Chairman of the board: Margareth Jorvid
Elicera Therapeutics develops cell and gene therapies armed with its patented iTANK platform, enabling a parallel immune attack against cancer. Lead candidate ELC-301 completed Phase I of the CARMA study in B-cell lymphoma: well tolerated, with objective responses in 10 of 11 patients, including patients relapsing after prior CAR T. Enrollment in Phase IIa is pending. In parallel, a first clinical study of the second candidate, ELC-401, in glioblastoma is being prepared. For CAR T and TCR-T developers, iTANK is a plug-in answer to antigen escape and immunosuppression in solid tumors, backed by first-in-human data and available under non-exclusive licenses.
ExpreS2ion Biotech
- CEO: Bent U. Frandsen
- Chairman of the board: Dr. Martin Roland Jensen
Patients with HER2-positive metastatic breast cancer still relapse as resistance emerges, leaving a clear unmet need. ExpreS2ion is advancing ES2B-C001, an active immunotherapy designed to induce a broad, polyclonal immune response against HER2, addressing tumour heterogeneity and resistance. In Phase I, we are seeing consistent, durable anti-HER2 immune responses, with an independent safety monitoring board supporting continued dose escalation. Built on our ExpreS2 platform – also underpinning grant-funded infectious disease programmes and business partnerships – ES2B-C001 is a differentiated asset with early clinical validation and meaningful upside in the established HER2 market.
Glycorex Transplantation
- CEO: Carl-Magnus Schultz
- Chairman of the board: Richard Lundin
Glycorex Transplantation AB (publ) (NGM: GTAB B) is a Swedish medtech pioneer with in-house R&D and manufacturing in Lund. Its proprietary immunoadsorption technology removes blood group antibodies. Flagship product Glycosorb® ABO facilitates blood group-incompatible organ and stem cell transplants—backed by 60+ publications and 8,000+ procedures across 30+ countries.Under new leadership focused on profitability, Glycorex is accelerating global expansion with new distribution in emerging markets. The platform is also scaling into universal blood components for transfusion centers, pre-hospital care, and military use.
Isofol Medical
- CEO: Petter Segelman Lindqvist
- Chairman of the board: Jan-Eric Österlund
Isofol is a clinical-stage biotechnology company dedicated to improving outcomes for patients with difficult-to-treat cancers. The company’s drug candidate, arfolitixorin, is a next-generation folate therapy designed to enhance the efficacy of established standard treatments for solid tumors. Arfolitixorin is initially and currently being evaluated in a Phase Ib/II clinical trial in metastatic colorectal cancer, the second leading cause of cancer-related death worldwide and an area of significant unmet medical need. Isofol is listed on Nasdaq Stockholm.
Lumito
- CEO: Sanne Wallenborg
- Chairman of the board: Kerstin Jakobsson
Orexo
- CEO: Nikolaj Sorensen
- Chairman of the board: Friedrich von Bohlen
Orexo is a Swedish pharmaceutical company. At the core of our innovation is AmorphOX®, an amorphous powder based proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm’s main market and trades as ADRs on the OTCQX market in the United States.
Oxcia
- CEO: Ulrika Warpman Berglund
- Chairman of the board: Eva Sjökvist Saers
Oxcia AB is a clinical-stage biotech company pioneering therapies that target key drivers of many diseases, using its proprietary O2-DDR platform (Oxidative stress, Oxidative DNA damage, and DNA Damage Response (DDR)). The platform has so far generated two first-in-class drug candidates: OXC-101, currently in clinical development for acute myeloid leukemia with both FDA and EMA Orphan Drug Designations, and OXC-201, a novel treatment for idiopathic pulmonary fibrosis supported by European Innovation Council funding. By addressing major unmet medical needs through a differentiated scientific approach, Oxcia aims to deliver transformative therapies to make life less short, creating significant value for patients and investors.
PharmNovo
- CEO: Per von Mentzer
- Chairman of the board: Johan Lund
PharmNovo is pioneering a pain-free future. Our breakthrough candidate, PN6047, is a first-in-class Delta Opioid Receptor Agonist (DORA) offering a safer, non-addictive solution for neuropathic pain. With an estimated global peak sales potential exceeding €2 billion by 2041, PN6047 represents a potential blockbuster opportunity and a highly attractive acquisition target. Awarded the EIC full blended financing support, PharmNovo has been recognized as one of the top European biotech companies, now Phase IIa-ready following CTA approval in Spain. PharmNovo is transforming pain management and advancing towards an exit opportunity by 2028 exceeding €1 billion.
redhot Diagnostics
- CEO: Nina E Beer
- Chairman of the board: Johan Ryden
redhot Diagnostics commercializes standardized kits for LC-MS/MS, the gold-standard method in clinical chemistry. Most laboratories still run these tests on in-house protocols, so results vary from one laboratory to the next, and IVDR is steadily closing that route. redhot replaces the protocols with validated, CE-marked kits.The lead product measures PEth, a substance formed only in the presence of alcohol, giving it 100 percent biochemical specificity and a detection window of several weeks. It is used in addiction medicine, liver and transplant clinics, and clinical trials. The kit is on the market today, generating recurring revenue at gross margins above 90 percent with almost no commercial effort behind it.Kits for drug monitoring and vitamin B12 deficiency are in development, alongside rhelise™, a patented home-sampling kit that keeps a blood sample stable for more than two weeks at room temperature. A further application filed in 2026 covers improved calibrators and controls.redhot diagnostics is raising capital to expand European and US distribution and build a multi-marker LC-MS/MS platform.
Saniona
- CEO: Thomas Feldthus
- Chairman of the board: John Haurum
Saniona (Nasdaq Stockholm: SANION) is a clinical-stage biopharmaceutical company developing ion channel medicines for neurological and psychiatric disorders. Its two wholly owned programs are preparing for Phase 1: SAN2668, a GABA-A α2/α3 PAM for severe paediatric epilepsies (DEE), and SAN2465, a GABA-A α5 NAM designed as a rapid-acting oral antidepressant for Major Depressive Disorder (MDD). Built on decades of ion channel research, Saniona’s platform has generated over SEK 1.2 billion in partnership income since 2012, including recent deals with Jazz and Acadia worth USD 70.5 million upfront and up to USD 1.6 billion in milestones. Saniona is funded to take both programs through Phase 1.
SampleFacts
- CEO: Maryam Poorafshar
- Chairman of the board: Gunilla Lundmark
SampleFacts brings together more than 100 years of combined experience providing a deep understanding of sample collection, workflows and the challenges faced by healthcare and research.Our patented solution enables instant separation of blood cells and plasma from a single drop of blood, at the point of collection, without centrifugation. With these characteristics the product provides a reliable and simple method for collecting and storing blood samples, addressing the growing demand for remote and patient centric sampling and biobanking.SampleFacts’ solution revolutionizes the way we take blood samples, where our technology transforms sample collection and storage empowering health care, research and military with accuracy, efficiency and limitless applications.
Sprint Bioscience
- CEO: Johan Emilsson
- Chairman of the board: Björn Sjöstrand
Sprint Bioscience develops small molecule, first in class drug programs with a focus on oncology. Using a fragment based drug discovery approach, the company develops drug programs in a time and resource efficient manner.The programs are partnered through licensing agreements, asset acquisitions, or research collaborations with global pharmaceutical companies during the preclinical phase, and the company has successfully entered into several such agreements.Sprint Bioscience is headquartered in Stockholm, Sweden, with laboratories located in Huddinge. The company’s shares are listed on Nasdaq First North Premier Growth Market (ticker: SPRINT).
Strike Pharma
- CEO: Per Norlén
- Chairman of the board: Magnus Persson
Pipeline of first in class in vivo CAR-M therapies based on a proprietary technology for targeted LNP delivery that improves potency and stability of products while reducing manufacturing costs.
Xbrane Biopharma
- CEO: Martin Åmark
- Chairman of the board: Anders Tullgren
Zelluna
- CEO: Namir Hassan
- Chairman of the board: Anders Tuv
